Catalent Pharma Solutions Joins PBOA
Cornell Stamoran, Catalent Pharma Solutions vice-president, is elected to the board of trustees of the Pharma & Biopharma Outsourcing Association.
The Pharma & Biopharma Outsourcing Association (PBOA) announced on April 8 that Catalent Pharma Solutions has joined the PBOA as a sustaining member. Cornell Stamoran, vice-president, corporate strategy and government affairs at Catalent and board member at Catalent Applied Drug Delivery Institute, has been elected to the PBOA’s Board of Trustees.
“Catalent Pharma Solutions is one of the world’s largest development and supply partners in the global pharmaceutical industry and we’re delighted to bring them into the Pharma & Biopharma Outsourcing Association,” said Gil Roth, president of the PBOA. “Cornell Stamoran’s extensive experience and strategic focus will be of great value to our Board as we advance our membership’s legislative, regulatory and business interests.”
“The outsourcing of drug product manufacturing has expanded significantly since I came to the advanced delivery technologies side of the industry in 1992. Today, outsourcing serves a critical role in ensuring consistent supply of prescription, OTC and consumer health products to our customers, and ultimately to patients. As a result, it is more important than ever for us to advocate for our interests, both legislative and regulatory. I’m pleased to represent Catalent, and to work to advance the Association’s goals, ” said Stamoran in a PBOA press statement.
Stamoran leads Catalent’s strategic planning and market intelligence efforts, and supports its government affairs, investor relations, global M&A and technology innovation, and acquisition activities. He has spent more than 25 years engaged with the health care industry, including 23 years in advanced drug and biologic delivery and outsourcing.
The Pharma & Biopharma Outsourcing Association is a nonprofit trade association dedicated to advancing the regulatory, legislative and general business interests of contract manufacturing organizations and contract development and manufacturing organizations.
Source: The Pharma & Biopharma Outsourcing Association
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
